Low impact
UniQure shares surge after FDA reverses course on Huntington's gene therapy approval pathway, allowing the company to proceed without a new study.
bloomberg-industries06/17, 06:27 PM
Your privacy choice
S7 Markets works without measurement. If you allow it, we count which screens are opened and which actions are taken, on our own domain and never anything you typed. You can change this in Settings at any time.
Read the privacy policyNews story
Low impact
bloomberg-industries06/17, 06:27 PM